Theratechnologies (NASDAQ:THTX) Stock Rating Lowered by Jones Trading

Jones Trading lowered shares of Theratechnologies (NASDAQ:THTX) from a strong-buy rating to a hold rating in a research report report published on Thursday, Marketbeat Ratings reports.

Theratechnologies Stock Performance

THTX stock opened at $3.13 on Thursday. The stock’s 50 day simple moving average is $2.61 and its 200 day simple moving average is $2.06. Theratechnologies has a fifty-two week low of $1.12 and a fifty-two week high of $3.20. The company has a market cap of $143.92 million, a P/E ratio of -39.13 and a beta of 0.55.

Institutional Trading of Theratechnologies

Several institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in shares of Theratechnologies in the first quarter worth approximately $39,000. Stonepine Capital Management LLC purchased a new stake in shares of Theratechnologies in the first quarter worth approximately $36,000. National Bank of Canada FI raised its stake in shares of Theratechnologies by 2.6% in the first quarter. National Bank of Canada FI now owns 197,068 shares of the company’s stock worth $282,000 after purchasing an additional 4,938 shares during the last quarter. Harbour Investments Inc. raised its stake in shares of Theratechnologies by 9.5% in the first quarter. Harbour Investments Inc. now owns 96,105 shares of the company’s stock worth $135,000 after purchasing an additional 8,333 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC purchased a new stake in shares of Theratechnologies in the first quarter worth approximately $42,000.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.